Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Plasma Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Chromosome 17 deletion 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 16 Dexamethasone 14 Melphalan 12 Bortezomib 11 Filgrastim 6 Peripheral Blood Stem Cell Transplantation 5 Lenalidomide 5 Thalidomide 4 Prednisone 4 sargramostim 3 fludarabine phosphate 3 daratumumab 3 Radiotherapy 3 Mycophenolic Acid 3 Interferon-alpha 3 Doxorubicin 3 Busulfan 3 Antilymphocyte Serum 3 pomalidomide 2 isatuximab 2 fludarabine 2 Vincristine 2 Methylprednisolone 2 Idarubicin 2 Cyclosporine 2 Carmustine 2 plerixafor 1 pegfilgrastim 1 orantinib 1 epoetin beta 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Neoplasms, Plasma Cell × Maintenance × Clear all

NCT01554852 2018-06-11

Myeloma XI

University of Leeds

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡